VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | The promise of novel checkpoint inhibitors for the treatment of HL

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses the promise of novel checkpoint inhibitors for the treatment of Hodgkin lymphoma (HL), drawing focus on the use of checkpoint inhibitors targeting PD-1, LAG-3 and TIM-3, as well as dual-targeting inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter